Takahiro Miura

Takahiro Miura

Auto-generated profile, based on publicly available information

Takahiro Miura

Department of Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2023 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
YSYuki Sasaki
Yuki Sasaki
Kosuke IshikawaKosuke Ishikawa
Kosuke Ishikawa
KHKanako C. Hatanaka
Kanako C. Hatanaka
YOYumiko Oyamada
Yumiko Oyamada
YSYusuke Sakuhara
Yusuke Sakuhara
SSSatoru Sasaki
Satoru Sasaki
Background: Klippel–Trenaunay syndrome (KTS) is a rare slow-flow combined vascular malformation with limb hypertrophy. KTS is thought to lie on the PIK3CA-related overgrowth spectrum, but reports are limited. PIK3CA encodes p110α, a catalytic subunit of phosphatidylinositol 3-kinase (PI3K) that plays an essential role in the PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway. We aimed to demonstrate the clinical utility of targeted next-generation sequencing (NGS) in identifying PIK3CA mosaicism in archival formalin-fixed paraffin-embedded (FFPE) tissues from patients with KTS. Results: Participants were 9 female and 5 male patients with KTS diagnosed as capillaro-venous malformation (CVM) or capillaro-lymphatico-venous malformation (CLVM). Median age at resection was 14 years (range, 5–57 years). Median archival period before DNA extraction from FFPE tissues was 5.4 years (range, 3–7 years). NGS-based sequencing of PIK3CA achieved an amplicon mean coverage of 119,000x. PIK3CA missense mutations were found in 12 of 14 patients (85.7%; 6/8 CVM and 6/6 CLVM), with 8 patients showing the hotspot variants E542K, E545K, H1047R, and H1047L. The non-hotspot PIK3CA variants C420R, Q546K, and Q546R were identified in 4 patients. Overall, the mean variant allele frequency for identified PIK3CA variants was 6.9% (range, 1.6–17.4%). All patients with geographic capillary malformation, histopathological lymphatic malformation or macrodactyly of the foot had PIK3CA variants. No genotype–phenotype association between hotspot and non-hotspot PIK3CA variants was found. Histologically, the vessels and adipose tissues of the lesions showed phosphorylation of the proteins in the PI3K/AKT/mTOR signaling pathway, including p-AKT, p-mTOR, and p-4EBP1. Conclusions: The PI3K/AKT/mTOR pathway in mesenchymal tissues was activated in patients with KTS. Amplicon-based targeted NGS could identify low-level mosaicism from low-input DNA extracted from FFPE tissues, potentially providing a diagnostic option for personalized medicine with inhibitors of the PI3K/AKT/mTOR signaling pathway.

1 August 2023 in Lymphatic Research and Biology
Verified
Journal Article
Closed access
YHYoshitada Hoshino
Yoshitada Hoshino
MOMasayuki Osawa
Masayuki Osawa
EFEmi Funayama
Emi Funayama
Kosuke IshikawaKosuke Ishikawa
Kosuke Ishikawa
TMTakahiro Miura
Takahiro Miura
TMTaku Maeda
Taku Maeda
Background: : Lymphedema is an intractable disease with no curative treatment available. Conservative treatment is the mainstay, and new drug treatment options are strongly needed. The purpose of this study was to investigate the effect of roxadustat, a prolyl-4-hydroxylase inhibitor, on lymphangiogenesis and its therapeutic effect on lymphedema in a radiation-free mouse hindlimb lymphedema model. Methods and Results: : Male C57BL/6N mice (8–10 weeks old) were used for the lymphedema model. Mice were randomized to an experimental group receiving roxadustat or a control group. The circumferential ratio of the hindlimbs was evaluated, and lymphatic flow of the hindlimbs was compared by fluorescent lymphography up to 28 days postoperatively. The roxadustat group showed an early improvement in hindlimb circumference and stasis of lymphatic flow. The number and area of lymphatic vessels on postoperative day 7 were significantly larger and smaller, respectively, in the roxadustat group compared with the control group. Skin thickness and macrophage infiltration on postoperative day 7 were significantly reduced in the roxadustat group compared with the control group. The relative mRNA expression of hypoxia-inducible factor-1α ( Hif-1α ), vascular endothelial growth factor receptor-3 ( VEGFR-3 ), vascular endothelial growth factor-C ( VEGF-C ), and Prospero homeobox 1 ( Prox1 ) on postoperative day 4 was significantly higher in the roxadustat group compared with the control group. Conclusions: : Roxadustat demonstrated a therapeutic effect in a murine model of hindlimb lymphedema through promotion of lymphangiogenesis through the activation of HIF-1α, VEGF-C, VEGFR-3, and Prox1, suggesting the potential of roxadustat as a therapeutic option in lymphedema.

18 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Kosuke IshikawaKosuke Ishikawa
Kosuke Ishikawa
TMTaku Maeda
Taku Maeda
EFEmi Funayama
Emi Funayama
NMNaoki Murao
Naoki Murao
TMTakahiro Miura
Takahiro Miura
SSSatoru Sasaki
Satoru Sasaki
Background: Treatment of oropharyngolaryngeal venous malformations (VMs) remains challenging. This study evaluated the effectiveness and safety of fluoroscopy- and endoscopy-guided transoral sclerotherapy for oropharyngolaryngeal VMs in a hybrid operation room (OR). Methods: Patients with oropharyngolaryngeal VMs who underwent transoral sclerotherapy in a hybrid OR were enrolled. Results: Fourteen patients (six females, eight males; median age of 26 years; range, 4–71 years) were analyzed. The symptoms observed were breathing difficulties (n = 3), snoring (n = 2), sleep apnea (n = 1), and swallowing difficulties (n = 1). Lesions were extensive in the face and neck (n = 9) and limited in the oropharyngolarynx (n = 5). A permanent tracheostomy was performed on two patients, while a temporary tracheostomy was performed on five patients. The treated regions were the soft palate (n = 8), pharynx (n = 7), base of the tongue (n = 4), and epiglottis (n = 1). The median number of sclerotherapy sessions was 2.5 (range, 1–9). The median follow-up duration was 81 months (range, 6–141). Treatment outcomes were graded as excellent (n = 2), good (n = 7), or fair (n = 5). The post-treatment complication was bleeding (n = 1), resulting in an urgent tracheostomy. Conclusions: Fluoroscopy- and endoscopy-guided transoral sclerotherapy in a hybrid OR can be effective and safe for oropharyngolaryngeal VMs.

2 November 2022 in Microsurgery
Verified
Journal Article
Closed access
EKErika G. Kusajima
Erika G. Kusajima
YYYuhei Yamamoto
Yuhei Yamamoto
KIKosuke Ishikawa
Kosuke Ishikawa
TMTakahiro Miura
Takahiro Miura
EFEmi Funayama
Emi Funayama
TMTaku Maeda
Taku Maeda

17 November 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YSYuki Sasaki
Yuki Sasaki
TMTaku Maeda
Taku Maeda
MHMasahiro Hojo
Masahiro Hojo
TMTakahiro Miura
Takahiro Miura
Kosuke IshikawaKosuke Ishikawa
Kosuke Ishikawa
YYYuhei Yamamoto
Yuhei Yamamoto

19 December 2025 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
SMSHINTARO MITAMURA
SHINTARO MITAMURA
Kosuke IshikawaKosuke Ishikawa
Kosuke Ishikawa
KHKanako C. Hatanaka
Kanako C. Hatanaka
TSTatsuro Saito
Tatsuro Saito
YSYuki Sasaki
Yuki Sasaki
YHYutaka Hatanaka
Yutaka Hatanaka